Metastatic castration-resistant prostate cancer (mCRPC) remains a significant health burden for men with critical need for novel targeted treatments Agreement adds a new preclinical ADC with potential ...
The Cambridge-GSK Translational Immunology Collaboration (CG-TIC) brings together GSK’s expertise in the science of the immune system, AI and clinical development with Cambridge’s complementary ...
GSK plc ("GSK") today announces the commencement of its share buyback programme (the “Programme”), as announced in its 2024 full year results announcement published on 5 February 2025 (the “FY24 ...
Data presented at IDWeek 2025 after study stopped early for efficacy Primary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment 1 A new oral option may ...
Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine to maintain viral suppression with 12 dosing days per year.
SARS-CoV-2 spike protein (B.1.351 strain) vaccine is the first and only protein-based variant COVID-19 booster vaccine approved in Great Britain and the European Union Results show the SARS-CoV-2 ...
Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £1.1 billion (+19%); Oncology £0.6 billion (+17%); HIV sales £2.1 billion (+10%) Vaccines sales £2.3 billion (+8%) ...
GSK plc (LSE/NYSE: GSK) today announced plans to establish a major new global R&D centre in Cambridge, UK, as part of the company’s plan to accelerate its R&D pipeline. The new 300,000 square foot ...
A vaccine candidate formulation demonstrated positive A and B strain immune responses relative to standard of care in both younger and older adults mRNA platform elicits strong overall antibody titres ...
Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA
Regulatory application supported by phase III B-Well trials demonstrating statistically significant and clinically meaningful functional cure rates in chronic hepatitis B Breakthrough Therapy ...
GSK plc (LSE/NYSE: GSK), with its development partner iTeos Therapeutics, Inc., has confirmed it is ending the development programme for belrestotug, an anti-TIGIT monoclonal antibody. The decision is ...
Company also announces it has now supplied 1.2 billion vaccines to Gavi, the Vaccine Alliance since 2010, helping to reach the world’s most vulnerable children. GSK is pleased to rank second in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results